Clinical trial
Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS
NCT04788745 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS
- Lead sponsor
- The University of Queensland
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 29, 2021
- Completion date
- May 24, 2023
- Enrollment
- 21 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.